Analyst Price Target is $6.33
▲ +1,431.64% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for ASLAN Pharmaceuticals in the last 3 months. The average price target is $6.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,431.64% upside from the last price of $0.41.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in ASLAN Pharmaceuticals. This Buy consensus rating has held steady for over two years.
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.